公开(公告)号：US20220340671A1

公开(公告)日：2022-10-27

申请号：US17695769

申请日：2022-03-15

Applicant: Pfizer Inc.

Inventor： Tracy Chia-Chien KUO ,  Bijan Andre Boldajipour ,  Javier Fernando Chaparro Riggers ,  Philippe Duchateau ,  Roman Galetto ,  Alexandre Juillerat ,  Thomas Charles Pertel ,  Arvind Rajpal ,  Barbra Johnson Sasu ,  Cesar Adolfo Sommer ,  Julien Valton ,  Thomas John Van Blarcom

IPC: C07K16/28 ,  C07K14/725 ,  C07K14/705 ,  A61K39/00 ,  A61K31/7076 ,  C12N15/63 ,  A61K35/17 ,  C12N5/10 ,  C12N5/0783

Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).

公开(公告)号：US11312782B2

公开(公告)日：2022-04-26

申请号：US16384719

申请日：2019-04-15

Applicant: Pfizer Inc.

Inventor： Tracy Chia-Chien Kuo ,  Bijan Andre Boldajipour ,  Javier Fernando Chaparro Riggers ,  Philippe Duchateau ,  Roman Ariel Galetto ,  Alexandre Juillerat ,  Thomas Charles Pertel ,  Arvind Rajpal ,  Barbra Johnson Sasu ,  Cesar Adolfo Sommer ,  Julien Valton ,  Thomas John Van Blarcom

IPC: C12N5/10 ,  C12N15/63 ,  C07K16/28 ,  C07K14/705 ,  C07K19/00 ,  C07K14/725 ,  A61K39/00 ,  A61K31/7076 ,  A61K35/17 ,  C12N5/0783 ,  A61K39/395 ,  A61K38/00

Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).

公开(公告)号：US20210324028A1

公开(公告)日：2021-10-21

申请号：US17356754

申请日：2021-06-24

Applicant: Pfizer Inc.

Inventor： Yik Andy Yeung ,  Reid Martin Renny Feldman ,  Ling Hon Matthew Chu ,  Javier Fernando Chaparro Riggers ,  Ivana Djuretic ,  Laura Lin ,  Lidia Mosyak

IPC: C07K14/54 ,  A61K35/17 ,  C07K19/00 ,  A61P35/00 ,  A61K38/17 ,  C07K16/32 ,  C07K16/28 ,  C07K14/55 ,  C12N15/62 ,  A61K38/19 ,  A61K39/395 ,  A61K38/20

Abstract: The present invention relates to human interleukin 15 (IL-15) variants that have therapeutic and diagnostic use, and methods for making thereof. The present invention also provides fusion proteins comprising a human IL-15 variant. Also provided are methods of stimulating or suppressing immune responses in a mammal, and methods of treating a disorder (e.g., cancer) using the IL-15 variants or the fusion protein of such IL-15 variants.

公开(公告)号：US10793635B2

公开(公告)日：2020-10-06

申请号：US16017974

申请日：2018-06-25

Applicant: PFIZER INC.

Inventor： Tracy Chia-Chien Kuo ,  Javier Fernando Chaparro Riggers ,  Wei Chen ,  Amy Shaw-Ru Chen ,  Edward Derrick Pascua ,  Thomas John Van Blarcom ,  Leila Marie Boustany ,  Weihsien Ho ,  Yik Andy Yeung ,  Pavel Strop ,  Arvind Rajpal

IPC: A61K39/395 ,  C07K16/28 ,  A61K31/454 ,  A61K31/704 ,  A61K31/69 ,  A61K47/68 ,  A61K39/00

Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.